OBJECTIVE: It has been proven that acetylsalicylic acid (aspirin), as a kind of classical non-steroidal anti-inflammatory drug, not only has the effect of anti-inflammatory, but also has the function of immunity regulation and mineralization. However, it needs further investigation to study how to delay release of aspirin for a long time and enable to promote bone regeneration. Herein, we demonstrated that the longterm delayed release pattern of aspirin through the construction of microsphere scaffolds is promising to achieve the excellent bone regeneration. METHODS: Here we synthesized three kinds of scaffolds as follows: (1) aspirin loaded calcium silicate (CaSiO₃) microsphere (CaSiO₃-aspirin) via simple immersion; (2) aspirin loaded polylactic-co-glycolic acid (PLGA) microsphere (PLGA-aspirin) via oil/water (O/W) emulsion; (3) aspirin loaded PLGA-CaSiO₃ scaffold (PLGA-CaSiO₃-aspirin) via O/W emulsion, optimal morphology and structure of PLGA-CaSiO₃-aspirin scaffold was acquired through modulating the ratio between PLGA and CaSiO₃. Furthermore, spectrophotometer was used to monitor the concentration of the extract of the three scaffolds for different releasing time, including 1, 2, 4, 6, 9, 13, 17, 21, 24, 30, 36, and 45 days, aspirin loading efficiency and its accumulation releasing curves were both achieved according to the concentration of aspirin. Their sustained release effects of aspirin were evaluated eventually. RESULTS: Environmental scanning electron microscope (ESEM) results showed that the surface structure of the three kinds of scaffolds were smooth and had uniform size distribution. In addition, a small amount of PLGA-aspirin microspheres occurred to aggregation, while a small amount of CaSiO₃-aspirin microspheres were broken. Moreover, the PLGA-aspirin microspheres in the PLGA-CaSiO₃-aspirin scaffolds were uniformly adhered to the surface of CaSiO₃ microspheres. The aspirin loadings of CaSiO₃-aspirin, PLGA-aspirin, and PLGA-CaSiO₃-aspirin were (1.06±0.04)%, (7.05±0.06)%, and (6.75±0.18)%, respectively. In addition, their corresponding time for releasing 95% of aspirin was 3, 24, and 36 days, respectively. The releasing time of PLGA-CaSiO₃-aspirin was longer than that of the others and the releasing rate was more stable. CONCLUSION The microsphere scaffold of PLGA-CaSiO₃-aspirin composites has excellent delayedrelease effect on aspirin, which is promising for using as osteogenic materials.
Aspirin ; Delayed-Action Preparations ; Lactic Acid ; Microspheres ; Polyglycolic Acid ; Polylactic Acid-Polyglycolic Acid Copolymer

ABSTRACT Various grafting materials are utilised to facilitate regeneration. There is currently a paradigm shift towards applying poly lactic-co-glycolic acid (PLGA), which is regarded as an excellent scaffold for tissue engineering. Concentrated growth factor (CGF) has also been reported to promote wound healing. Nevertheless, the role of PLGA microspheres as a substitute for bone graft material with CGF in bone regeneration remains unclear. This study was designed to evaluate the effect of CGF with PLGA on bone formation and the expression of alkaline phosphatase (ALP) following socket preservation. PLGA microspheres were prepared using double solvent evaporation method and observed under scanning electron microscopy (SEM). A 6 mL of rabbit’s blood was collected from the marginal ear vein and centrifuged to obtain CGF. Blood was also collected for ALP assessment from 24 New Zealand White (NZW) male rabbits subjected to the first upper left premolar extraction. Sockets were filled with CGF, PLGA, CGF+PLGA or left empty and observed with microscopic computed tomography (micro-CT) at four weeks and eight weeks. The SEM image revealed a spherical shape with interconnected pores on the surface of the PLGA particles. Repeated measures ANOVA were used to evaluate the effect of time and treatment (p < 0.05) with significant differences in bone width, height, volume, volume fraction and expression of ALP was observed with CGF+PLGA. Both CGF and PLGA have the potential as the alternative grafting materials and this study could serve as an ideal benchmark for future investigations on the role of CGF+PLGA in bone regeneration enhancement.
Bone Regeneration ; Platelet-Derived Growth Factor ; Polylactic Acid-Polyglycolic Acid Copolymer

OBJECTIVE: To construct a biodegradable PLGA nerve conduit (NC) filled with NSCs in order to improve facial nerve regeneration. METHOD: SD rats were subjected to right facial nerve transection, and PLGA NCs filled with NSCs were used to bridge the nerve gap. Facial nerve regeneration was assessed 4 and 12 weeks after surgery, through electrophysiological testing, and morphometric analysis of axons. RESULT: Nerve action potential amplitude, and axonal area were significantly greater in the NSCs group than the empty NC group. CONCLUSION NSCs transplantation may improve regeneration of the facial nerve.
Animals ; Facial Nerve Injuries ; surgery ; Female ; Lactic Acid ; Nerve Regeneration ; Neural Stem Cells ; transplantation ; Polyglycolic Acid ; Polylactic Acid-Polyglycolic Acid Copolymer ; Pregnancy ; Rats ; Rats, Sprague-Dawley

OBJECTIVE: To investigate a new way to yield plenty of high purity olfactory ensheathing cells (OECs) and its biocompatibility with appropriate scaffolds. METHODS: OECs were prepared from neonatal Wister rats and co-cultured with poly [LA-co-(Glc-alt-Lys)] (PLGL). Its contact angle, adherent rate, and activity rate were tested. RESULTS: The contact angle of poly (D, L-lactic acid) (PDLLA) (84.5 degree+/-1.5 degree) was significantly higher than that of PLGL (52.6 degree+/-0.8 degree), the adherent rate of PLGL (80%) was significantly higher than that of the PDLLA (57%), and the activity rate of PLGL (88%) was much higher than that of the PDLLA (76%). CONCLUSION PLGL possesses better hydrophilicity and biocompatibility than PDLLA, and it can provide a better cell growth circumstance which is helpful for the effective treatment of nerve injury.
Animals ; Animals, Newborn ; Biocompatible Materials ; Cells, Cultured ; Lactic Acid ; chemical synthesis ; pharmacology ; Nerve Regeneration ; Olfactory Bulb ; cytology ; Polyglycolic Acid ; chemical synthesis ; pharmacology ; Polylactic Acid-Polyglycolic Acid Copolymer ; Rats ; Rats, Wistar ; Spinal Cord Injuries ; physiopathology ; Tissue Engineering ; methods ; Tissue Scaffolds ; chemistry

OBJECTIVE: To prepare the slow-release complex with rifampicin (RFP)-polylactic-co-glycolic acid (PLGA)-calcium phosphate cement (CPC) (RFP-PLGA-CPC complex), and to study its physical and chemical properties and drug release properties in vitro.
 METHODS: The emulsification-solvent evaporation method was adopted to prepare rifampicin polylactic acid-glycolic acid (RFP-PLGA) slow-release microspheres, which were divided into 3 groups: a calcium phosphate bone cement group (CPC group), a CPC embedded with RFP group (RFP-CPC group), and a PLGA slow-release microspheres carrying RFP and the self-curing CPC group (RFP- PLGA-CPC complex group). The solidification time and porosity of materials were determined. The drug release experiments in vitro were carried out to observe the compressive strength, the change of section morphology before and after drug release. 
 RESULTS: The CPC group showed the shortest solidification time, while the RFP-PLGA-CPC complex group had the longest one. There was statistical difference in the porosity between the CPC group and the RFP-CPC group (P<0.05); Compared to the RFP-PLGA-CPC complex group, the porosity in the CPC group and the RFP-CPC group were significantly changed (both P<0.01). There was significant difference in the compressive strength between the RFP- PLGA-CPC complex group and the CPC group (P<0.01), while there was significant difference in the compressive strength between the RFP-CPC group and the CPC group (3 days: P<0.05; 30 and 60 days: P<0.01). The change of the compressive strength in the CPC was not significant in the whole process of degradation. The sizes of PLGA microspheres were uniform, with the particle size between 100-150 μm. The microspheres were spheres or spheroids, and their surface was smooth without the attached impurities. There was no significant change in the section gap in the CPC group after soaking for 3 to 60 days. The microstructure change in the RFP-CPC group was small, and the cross section was formed by small particles. The pores of section in the RFP-PLGA-CPC complex group increased obviously, and PLGA microspheres gradually disappeared until the 60th day when there were only empty cavities left. The RFP-PLGA-CPC complex group had no obvious drugs sudden release, and the cumulative drug release rate was nearly 95% in the 60 days. The linear fitting was conducted for the drug release behavior of the complex, which was in accordance with zero order kinetics equation F=0.168×t.
 CONCLUSION The porosity of RFP-PLGA-CPC complex is significantly higher than that of CPC, and it can keep slow release of the effective anti-tuberculosis drugs and maintain a certain mechanical strength for a long time.
Bone Cements ; pharmacokinetics ; Calcium Phosphates ; pharmacokinetics ; Compressive Strength ; Delayed-Action Preparations ; pharmacokinetics ; Dental Cements ; pharmacokinetics ; Lactic Acid ; pharmacokinetics ; Materials Testing ; Microspheres ; Polyglycolic Acid ; pharmacokinetics ; Polylactic Acid-Polyglycolic Acid Copolymer ; Porosity ; Rifampin ; administration & dosage ; pharmacokinetics

OBJECTIVE: To verrify the anti-tumor efficacy and toxicity between juglone (Jug) and Jug-loaded PLGA nanoparticles (Jug-PLGA-NPs). METHODS: Jug-PLGA-NPs were prepared by ultrasonic emulsification. The anti-tumor activity of Jug (2, 3, 4 µg/mL) and Jug-PLGA-NPs (Jug: 2, 3, 4 µg/mL) in vitro was measured by MTT assay and cell apoptosis analysis. The distribution, anti-tumor effect and biological safety in vivo was evaluated on A375 nude mice. RESULTS: With the advantage of good penetration and targeting properties, Jug-PLGA-NPs significantly inhibited proliferation and migration of melanoma cells both in vitro and in vivo (P<0.05 or P<0.01) with acceptable biocompatibility. CONCLUSIONS Jug can inhibit the growth of melanoma but is highly toxic. With the advantage of sustained release, tumor targeting, anti-tumor activity and acceptable biological safety, Jug-PLGA-NPs provide a new pharmaceutical form for future application of Jug.
Animals ; Cell Line, Tumor ; Delayed-Action Preparations/therapeutic use* ; Drug Carriers/therapeutic use* ; Melanoma/pathology* ; Mice ; Mice, Nude ; Nanoparticles ; Naphthoquinones ; Particle Size ; Polylactic Acid-Polyglycolic Acid Copolymer/therapeutic use*

As the carrier of water-insoluble drugs, microspheres can play a role in increasing solubility and delaying releasing essence. The objective of this study was to improve the solubility and to delay the release of a newly discovered antitumor compound 3β-hydroxyolea-12-en-28-oic acid-3, 5, 6-trimethylpyrazin-2-methyl ester (T-OA). Early-stage preparation discovery concept (EPDC) was employed in the present study. The preparation, physicochemical characterization, and drug release properties of PLGA microspheres were evaluated. T-OA-loaded PLGA microspheres were prepared by an oil-in-water (O/W) emulsification solvent evaporation method. Characterization and release behaviors of the T-OA PLGA microspheres were evaluated by X-ray diffract (XRD), differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), and high performance liquid chromatography (HPLC). The results demonstrated that T-OA-loaded PLGA microspheres could be successfully obtained through solvent evaporation method with appropriate morphologic characteristics and high encapsulation efficiency. The XRD analysis showed that T-OA would be either molecularly dispersed in the polymer or distributed in an amorphous form. The DSC and FTIR analysis proved that there were interactions between T-OA and PLGA polymer. SEM observations displayed the morphology of the microspheres was homogeneous and the majority of the spheres ranged between 50 and 150 μm. The drug release behavior of the microspheres in the phosphate buffered saline medium exhibited a sustained release and the duration of the release lasted for more than 23 days, which was fit with zero-order release pattern with r = 0.9947. In conclusion, TOA-loaded PLGA microspheres might hold great promise for using as a drug-delivery system in biomedical applications.
Antineoplastic Agents ; chemistry ; Calorimetry, Differential Scanning ; Chemistry, Pharmaceutical ; Delayed-Action Preparations ; chemistry ; Drug Carriers ; chemical synthesis ; chemistry ; Lactic Acid ; chemical synthesis ; chemistry ; Microscopy, Electron, Scanning ; Microspheres ; Oleanolic Acid ; chemistry ; Polyglycolic Acid ; chemical synthesis ; chemistry ; Polylactic Acid-Polyglycolic Acid Copolymer ; Pyrazines ; chemistry ; Solubility ; Spectroscopy, Fourier Transform Infrared ; X-Ray Diffraction

Animals ; Antigens, Neoplasm ; chemistry ; immunology ; Cancer Vaccines ; chemistry ; therapeutic use ; Cell Line, Tumor ; CpG Islands ; Cytotoxicity, Immunologic ; Dendritic Cells ; immunology ; metabolism ; Humans ; In Vitro Techniques ; Lactic Acid ; chemistry ; Leukemia ; immunology ; therapy ; Lymphocytes ; cytology ; immunology ; Nanoparticles ; chemistry ; Peptides ; chemistry ; immunology ; therapeutic use ; Polyglycolic Acid ; chemistry ; Polylactic Acid-Polyglycolic Acid Copolymer ; WT1 Proteins ; chemistry ; immunology